Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 5/20 | 0.33 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | TACR3 | P29371 | 2/20 | 0.30 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.30 |
| ▸ | TACR1 | P25103 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24454059 | 1.00 | FURIN (0.33) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL25070715 | 0.90 | FURIN (0.31) | FURINC3AR1SMN1; SMN2SIRT5 | |
| SCHEMBL15499750 | 0.90 | SIRT5 (0.34) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL24469384 | 0.90 | SIRT5 (0.34) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL18824024 | 0.89 | FURIN (0.31) | FURINC3AR1 | |
| SCHEMBL21013102 | 0.89 | FURIN (0.32) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL22068521 | 0.89 | FURIN (0.32) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL18594644 | 0.89 | FURIN (0.32) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL22030651 | 0.88 | FURIN (0.34) | FURINC3AR1LMNAPOLBKMT2A | |
| SCHEMBL25070716 | 0.86 | FURIN (0.32) | FURINC3AR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2023-08-31 | — | — | US | disclosed |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | NOVARTIS AG (CH) | 2022-05-26 | — | — | US | disclosed |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2021-11-11 | — | — | US | disclosed |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | NOVARTIS AG (CH) | 2021-04-13 | — | — | US | disclosed |
| US-20200338207-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | NOVARTIS AG (CH) | 2020-10-29 | — | — | US | disclosed |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | NOVARTIS AG (CH) | 2020-05-28 | — | — | US | disclosed |
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2019-11-05 | — | — | US | disclosed |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2019-05-16 | — | — | US | disclosed |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | NOVARTIS AG (CH) | 2019-05-07 | — | — | US | disclosed |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-9938323-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | NOVARTIS AG (CH) | 2018-04-10 | — | — | US | disclosed |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | NOVARTIS AG (CH) | 2017-08-03 | — | — | US | disclosed |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | NOVARTIS AG (CH) | 2017-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464969-B2 | Amatoxin derivatives and conjugates thereof as inhibitors of RNA polymerase | RNGTT, RNASE1, RNMT | FURIN 1526/4885C3AR1 34/4885LMNA 2108/4885 |
| US-20170121421-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | FURIN 3280/4885C3AR1 93/4885LMNA 3839/4885 |
| US-20230270876-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | FURIN 274/4885C3AR1 743/4885LMNA 4106/4885 |
| US-20210346387-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST | TLR3, TLR2, TLR9 | FURIN 3280/4885C3AR1 93/4885LMNA 3839/4885 |
| US-10973826-B2 | Antibody conjugates comprising toll-like receptor agonist | TLR3, TLR2, TLR9 | FURIN 3280/4885C3AR1 93/4885LMNA 3839/4885 |
| US-20190144504-A1 | AMATOXIN DERIVATIVES AND CONJUGATES THEREOF AS INHIBITORS OF RNA POLYMERASE | RNGTT, RNASE1, RNMT | FURIN 1526/4885C3AR1 34/4885LMNA 2108/4885 |
| US-20180155281-A1 | CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF | CD47, MKI67, NGLY1 | FURIN 594/4885C3AR1 185/4885LMNA 3714/4885 |
| US-20200338207-A1 | SPECIFIC SITES FOR MODIFYING ANTIBODIES TO MAKE IMMUNOCONJUGATES | PTMS, FCGR2A, FCGR3B | FURIN 274/4885C3AR1 743/4885LMNA 4106/4885 |
| US-20220162308-A1 | ANTI-CD48 ANTIBODIES, ANTIBODY DRUG CONJUGATES, AND USES THEREOF | ITGB8, ITGA8, CD4 | FURIN 708/4885C3AR1 213/4885LMNA 2433/4885 |
| US-20200164084-A1 | ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST AND COMBINATION THERAPIES | TLR3, TLR2, TLR9 | FURIN 2759/4885C3AR1 62/4885LMNA 3516/4885 |
| US-10280139-B2 | Cytotoxic peptides and conjugates thereof | CD47, MKI67, NGLY1 | FURIN 594/4885C3AR1 185/4885LMNA 3714/4885 |
| US-20170218085-A1 | SITE-SPECIFIC LABELING METHODS AND MOLECULES PRODUCED THEREBY | PTMS, DNPEP, PSAT1 | FURIN 543/4885C3AR1 2062/4885LMNA 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.